Traws Pharma, Inc. (TRAW) — SEC Filings
Traws Pharma, Inc. (TRAW) — 50 SEC filings. Latest: 8-K (Apr 15, 2026). Includes 40 8-K, 3 DEF 14A, 3 10-Q.
View Traws Pharma, Inc. on SEC EDGAR
Overview
Traws Pharma, Inc. (TRAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 15, 2026: Traws Pharma, Inc. filed an 8-K on April 15, 2026, reporting a material definitive agreement, unregistered sales of equity securities, and other events. The filing includes various exhibits such as the 8-K document itself, and several exhibits related to agreements and financial statements.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Traws Pharma, Inc. is neutral.
Filing Type Overview
Traws Pharma, Inc. (TRAW) has filed 40 8-K, 3 DEF 14A, 3 10-Q, 1 10-K/A, 1 10-K, 1 SC 13D/A, 1 SC 13D with the SEC between Aug 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of TRAW's 44 recent filings, 4 were flagged as high-risk, 19 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2,790,000 |
| Net Income | $20,575,000 |
| EPS | $2.00 |
| Debt-to-Equity | 0.89 |
| Cash Position | $13,081,000 |
| Operating Margin | -231.3% |
| Total Assets | $15,622,000 |
| Total Debt | $7,360,000 |
Key Executives
- Iain Dukes
- Dr. Jonathan R. T. Macarthur
- Dr. David J. E. Macarthur
- Dr. Steven A. Deitcher
- Dr. Richard E. G. Smith
- Ms. Jennifer L. Simpson
Industry Context
Traws Pharma operates within the pharmaceutical industry, a sector characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. The industry is constantly evolving with advancements in biotechnology, personalized medicine, and global health challenges, requiring companies to adapt their strategies and product pipelines.
Top Tags
pharmaceutical (9) · 8-K (8) · corporate-filing (7) · corporate-governance (5) · management-change (5) · financial-reporting (5) · sec-filing (5) · corporate-action (4) · material-agreement (3) · company-update (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC Accession Number | 0001104659-26-043497 | Unique identifier for the filing |
| Common Stock Shares Outstanding | 7,125,832 | As of the October 2, 2025 Record Date, each entitled to one vote. |
| Series C Preferred Stock Shares Outstanding | 6,737.1410 | As of the October 2, 2025 Record Date, not entitled to vote. |
| Number of Directors | 7 | Proposed for election until the 2026 Annual Meeting. |
| Fiscal Year for Auditor Ratification | 2025 | KPMG LLP selected for the fiscal year ending December 31, 2025. |
| Quorum Requirement | 33 1/3% | Percentage of shares entitled to vote required for a quorum at the Annual Meeting. |
| Proxy Voting Deadline | November 20, 2025 | 11:59 p.m. Eastern Time for Internet and telephone votes. |
| Proxy Materials Mailing Date | October 8, 2025 | Date Notice of Internet Availability of Proxy Materials was mailed. |
| Annual Meeting Start Time | 9:00 a.m. ET | On Friday, November 21, 2025. |
| Net income for six months ended June 30, 2025 | $20,575,000 | Significant turnaround from a $128,126,000 net loss in the prior year. |
| Cash and cash equivalents as of June 30, 2025 | $13,081,000 | Represents a decrease from $21,338,000 at December 31, 2024, and is insufficient for more than one year of operations. |
| Revenue for six months ended June 30, 2025 | $2,790,000 | Substantial increase from $113,000 in the prior-year period. |
| Change in fair value of warrant liability for six months ended June 30, 2025 | $26,659,000 | Major non-cash contributor to net income. |
| Accumulated deficit as of June 30, 2025 | $628,579,000 | Indicates historical losses despite recent net income. |
| Outstanding shares of Common Stock as of August 12, 2025 | 7,063,829 | Reflects share count after various equity activities. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Traws Pharma, Inc. (TRAW)?
Traws Pharma, Inc. has 50 recent SEC filings from Aug 2024 to Apr 2026, including 40 8-K, 3 DEF 14A, 3 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TRAW filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Traws Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Traws Pharma, Inc. (TRAW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Traws Pharma, Inc.?
Key financial highlights from Traws Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TRAW?
The investment thesis for TRAW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Traws Pharma, Inc.?
Key executives identified across Traws Pharma, Inc.'s filings include Iain Dukes, Dr. Jonathan R. T. Macarthur, Dr. David J. E. Macarthur, Dr. Steven A. Deitcher, Dr. Richard E. G. Smith and 1 others.
What are the main risk factors for Traws Pharma, Inc. stock?
Of TRAW's 44 assessed filings, 4 were flagged high-risk, 19 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Traws Pharma, Inc.?
Forward guidance and predictions for Traws Pharma, Inc. are extracted from SEC filings as they are enriched.